T1	tradename 112 119	PEGASYS
T2	tradename 181 199	PEGASYS. PEGASYS
T3	nanoparticle 201 223	peginterferon alfa-2a)
T4	routeofadministration 239 251	subcutaneous
T5	fdaapprovaldate 279 283	2002
T6	adversereaction 467 507	neuropsychiatric, autoimmune, ischemic,
T7	adversereaction 512 533	infectious disorders.
T8	co-administereddrug 895 904	Ribavirin
T9	tradename 1057 1057	
T10	indication 1103 1128	Chronic Hepatitis C (CHC)
T11	tradename 1290 1297	PEGASYS
T12	indication 1339 1342	CHC
T13	indication 1489 1543	HBeAg positive and HBeAg negative chronic hepatitis B
T14	tradename 1734 1741	PEGASYS
T15	routeofadministration 1761 1773	subcutaneous
T16	indication 1821 1824	CHC
T17	indication 1828 1854	chronic hepatitis B (CHB),
T18	tradename 1855 1862	PEGASYS
T19	dose 1876 1883	180 mcg
T20	frequency 1884 1892	per week
T21	indication 2067 2071	CHC,
T22	tradename 2072 2079	PEGASYS
T23	dose 2092 2107	180 mcg/1.73 m2
T24	frequency 2114 2123	per week,
T25	co-administereddrug 2144 2154	ribavirin,
T26	tradename 3230 3237	Pegasys
T27	co-administereddrug 3273 3282	Ribavirin
T28	co-administereddrug 3453 3462	Ribavirin
T29	tradename 3648 3655	PEGASYS
T30	adversereaction 3847 3873	Neuropsychiatric reactions
T31	adversereaction 3890 3914	Cardiovascular disorders
T32	adversereaction 3931 3954	Bone marrow suppression
T33	adversereaction 3971 4005	Autoimmune and endocrine disorders
T34	adversereaction 4017 4051	thyroid disorders; hyperglycemia)
T35	adversereaction 4073 4097	Ophthalmologic disorders
T36	adversereaction 4114 4139	Cerebrovascular disorders
T37	adversereaction 4156 4201	Hepatic decompensation in cirrhotic patients.
T38	adversereaction 4214 4257	 of hepatitis during hepatitis B treatment
T39	adversereaction 4274 4293	Pulmonary disorders
T40	adversereaction 4311 4348	Infections (bacterial, viral, fungal)
T41	adversereaction 4366 4373	Colitis
T42	adversereaction 4378 4390	pancreatitis
T43	adversereaction 4414 4430	Hypersensitivity
T44	adversereaction 4435 4457	serious skin reactions
T45	adversereaction 4468 4493	Stevens-Johnson syndrome
T46	adversereaction 4511 4528	Growth impairment
T47	adversereaction 4593 4614	Peripheral neuropathy
T48	co-administereddrug 4645 4656	telbivudine
T49	adversereaction 4821 4856	fatigue/asthenia, pyrexia, myalgia,
T50	adversereaction 4861 4870	headache.
T51	company 5036 5045	Genentech
T52	co-administereddrug 5328 5338	Methadone:
T53	co-administereddrug 5373 5382	methadone
T54	tradename 5497 5504	PEGASYS
T55	co-administereddrug 5508 5517	ribavirin
T56	co-administereddrug 5568 5579	Zidovudine:
T57	tradename 5634 5641	PEGASYS
T58	co-administereddrug 5649 5659	ribavirin(
T59	adversereaction 5896 5922	Neuropsychiatric, cardiac,
T60	adversereaction 5927 5965	systemic (flu-like) adverse reactions
T61	tradename 6224 6231	PEGASYS
T62	indication 6335 6355	Chronic Hepatitis B:
T63	indication 7015 7034	Chronic Hepatitis C
T64	indication 7040 7059	Chronic Hepatitis B
T65	indication 7135 7138	CHC
T66	indication 7168 7171	CHC
T67	indication 7177 7196	Chronic Hepatitis B
T68	co-administereddrug 7361 7370	Ribavirin
T69	adversereaction 7376 7392	Neuropsychiatric
T70	adversereaction 7398 7422	Cardiovascular Disorders
T71	adversereaction 7428 7451	Bone Marrow Suppression
T72	adversereaction 7457 7477	Autoimmune Disorders
T73	adversereaction 7483 7502	Endocrine Disorders
T74	adversereaction 7508 7532	Ophthalmologic Disorders
T75	adversereaction 7538 7563	Cerebrovascular Disorders
T76	adversereaction 7569 7584	Hepatic Failure
T77	adversereaction 7589 7612	Hepatitis Exacerbations
T78	adversereaction 7619 7638	Pulmonary Disorders
T79	adversereaction 7645 7655	Infections
T80	adversereaction 7662 7669	Colitis
T81	adversereaction 7676 7688	Pancreatitis
T82	adversereaction 7695 7711	Hypersensitivity
T83	adversereaction 7718 7734	Impact on Growth
T84	adversereaction 7763 7784	Peripheral Neuropathy
T85	co-administereddrug 7979 7991	Theophylline
T86	co-administereddrug 7997 8006	Methadone
T87	indication 8222 8241	Chronic Hepatitis B
T88	indication 8502 8521	Chronic Hepatitis C
T89	tradename 8543 8551	PEGASYS/
T90	co-administereddrug 8551 8558	COPEGUS
T91	indication 8586 8605	Chronic Hepatitis C
T92	indication 8632 8636	CHC/
T93	tradename 8652 8659	PEGASYS
T94	tradename 8676 8684	PEGASYS/
T95	co-administereddrug 8684 8691	COPEGUS
T96	indication 8720 8739	Chronic Hepatitis C
T97	tradename 8760 8767	PEGASYS
T98	indication 8786 8805	Chronic Hepatitis B
T99	tradename 8823 8830	PEGASYS
T100	tradename 9314 9321	PEGASYS
T101	nanoparticle 9323 9345	peginterferon alfa-2a)
T102	adversereaction 9396 9435	neuropsychiatric, autoimmune, ischemic,
T103	adversereaction 9440 9461	infectious disorders.
T104	tradename 9734 9741	PEGASYS
T105	indication 9904 9923	Chronic Hepatitis C
T106	tradename 9924 9932	PEGASYS,
T107	indication 10064 10089	chronic hepatitis C (CHC)
T108	tradename 10231 10239	PEGASYS,
T109	tradename 10280 10287	PEGASYS
T110	co-administereddrug 10308 10317	ribavirin
T111	indication 10397 10400	CHC
T112	tradename 10432 10439	PEGASYS
T113	indication 10505 10508	CHC
T114	tradename 10659 10666	PEGASYS
T115	co-administereddrug 10696 10705	ribavirin
T116	indication 10796 10799	CHC
T117	tradename 10865 10872	PEGASYS
T118	indication 10923 10926	CHC
T119	indication 11016 11041	Chronic Hepatitis B (CHB)
T120	tradename 11042 11049	PEGASYS
T121	indication 11104 11157	HBeAg-positive and HBeAg-negative chronic hepatitis B
T122	tradename 11321 11328	PEGASYS
T123	routeofadministration 11332 11344	subcutaneous
T124	frequency 11355 11366	once weekly
T125	indication 11444 11469	chronic hepatitis C (CHC)
T126	indication 11580 11583	CHC
T127	indication 11657 11682	chronic hepatitis B (CHB)
T128	indication 11740 11744	CHC,
T129	tradename 11749 11756	PEGASYS
T130	tradename 11976 11983	PEGASYS
T131	indication 12034 12037	CHC
T132	indication 12172 12175	CHC
T133	indication 12179 12183	CHB:
T134	tradename 12798 12805	PEGASYS
T135	indication 12938 12957	Chronic Hepatitis C
T136	indication 12980 12983	CHC
T137	tradename 13064 13071	PEGASYS
T138	indication 13117 13120	CHC
T139	tradename 13208 13215	PEGASYS
T140	co-administereddrug 13236 13245	ribavirin
T141	tradename 13605 13612	PEGASYS
T142	tradename 13704 13711	PEGASYS
T143	tradename 13828 13835	PEGASYS
T144	indication 13840 13843	CHC
T145	tradename 13883 13890	PEGASYS
T146	tradename 13898 13905	PEGASYS
T147	dose 13932 13939	180 mcg
T148	routeofadministration 13940 13952	subcutaneous
T149	frequency 13983 13994	once weekly
T150	tradename 14148 14155	PEGASYS
T151	indication 14210 14214	CHC,
T152	tradename 14396 14403	PEGASYS
T153	co-administereddrug 14408 14417	ribavirin
T154	tradename 14516 14523	PEGASYS
T155	co-administereddrug 14528 14537	ribavirin
T156	tradename 14634 14641	PEGASYS
T157	indication 14679 14683	CHC,
T158	tradename 14700 14707	PEGASYS
T159	dose 14718 14725	180 mcg
T160	routeofadministration 14730 14742	subcutaneous
T161	frequency 14773 14798	once weekly for 48 weeks.
T162	indication 14822 14825	CHC
T163	tradename 14863 14870	PEGASYS
T164	indication 14893 14896	CHC
T165	dose 14920 14927	180 mcg
T166	routeofadministration 14928 14942	subcutaneously
T167	tradename 14983 14990	PEGASYS
T168	tradename 15228 15236	PEGASYS)
T169	tradename 15241 15248	PEGASYS
T170	indication 15415 15418	CHC
T171	tradename 15420 15427	PEGASYS
T172	dose 15447 15462	180 mcg/1.73 m2
T173	routeofadministration 15469 15483	subcutaneously
T174	frequency 15484 15496	once weekly,
T175	dose 15518 15526	180 mcg,
T176	co-administereddrug 15922 15931	ribavirin
T177	indication 16169 16194	Chronic Hepatitis B (CHB)
T178	tradename 16212 16219	PEGASYS
T179	indication 16242 16245	CHB
T180	dose 16249 16256	180 mcg
T181	routeofadministration 16257 16271	subcutaneously
T182	frequency 16272 16283	once weekly
T183	tradename 16472 16479	PEGASYS
T184	tradename 16810 16817	PEGASYS
T185	tradename 16938 16945	PEGASYS
T186	dose 16998 17005	135 mcg
T187	routeofadministration 17006 17020	subcutaneously
T188	frequency 17021 17032	once weekly
T189	dose 17147 17153	90 mcg
T190	routeofadministration 17154 17168	subcutaneously
T191	frequency 17169 17180	once weekly
T192	dose 17257 17263	90 mcg
T193	routeofadministration 17264 17278	subcutaneously
T194	frequency 17279 17290	once weekly
T195	indication 17612 17615	CHC
T196	tradename 17693 17700	PEGASYS
T197	dose 17722 17729	135 mcg
T198	tradename 17804 17811	PEGASYS
T199	tradename 18104 18111	PEGASYS
T200	dose 18115 18122	135 mcg
T201	tradename 18169 18176	PEGASYS
T202	tradename 18519 18526	PEGASYS
T203	tradename 18908 18915	PEGASYS
T204	tradename 19413 19420	PEGASYS
T205	dose 19441 19448	135 mcg
T206	dose 19450 19465	135 mcg/1.73 m2
T207	dose 19499 19505	90 mcg
T208	frequency 19506 19517	once weekly
T209	dose 19519 19533	90 mcg/1.73 m2
T210	tradename 19584 19591	PEGASYS
T211	dose 19602 19609	135 mcg
T212	dose 19611 19626	135 mcg/1.73 m2
T213	dose 19660 19666	90 mcg
T214	dose 19668 19682	90 mcg/1.73 m2
T215	frequency 19713 19724	once weekly
T216	tradename 20037 20044	PEGASYS
T217	tradename 20078 20085	PEGASYS
T218	tradename 20303 20310	PEGASYS
T219	indication 20442 20446	CHC.
T220	tradename 20680 20687	PEGASYS
T221	tradename 20819 20826	PEGASYS
T222	dose 20919 20934	135 mcg/1.73 m2
T223	dose 21081 21096	135 mcg/1.73 m2
T224	dose 21201 21216	135 mcg/1.73 m2
T225	dose 21323 21337	90 mcg/1.73 m2
T226	dose 21424 21439	135 mcg/1.73 m2
T227	dose 21584 21598	90 mcg/1.73 m2
T228	tradename 22029 22037	PEGASYS,
T229	tradename 22592 22599	PEGASYS
T230	tradename 22687 22694	PEGASYS
T231	dose 22722 22729	180 mcg
T232	frequency 22730 22741	once weekly
T233	dose 22801 22808	135 mcg
T234	frequency 22809 22820	once weekly
T235	dose 22881 22888	135 mcg
T236	frequency 22889 22900	once weekly
T237	tradename 22969 22976	PEGASYS
T238	dose 23000 23006	90 mcg
T239	frequency 23007 23018	once weekly
T240	tradename 23099 23106	PEGASYS
T241	routeofadministration 23374 23386	subcutaneous
T242	routeofadministration 23412 23426	subcutaneously
T243	tradename 23444 23451	PEGASYS
T244	tradename 23556 23563	PEGASYS
T245	tradename 23743 23750	PEGASYS
T246	dose 23895 23914	180, 135, or 90 mcg
T247	frequency 23915 23927	once weekly)
T248	tradename 23961 23968	PEGASYS
T249	tradename 24121 24128	PEGASYS
T250	tradename 24150 24157	PEGASYS
T251	tradename 24166 24173	PEGASYS
T252	tradename 24757 24764	PEGASYS
T253	tradename 24971 24979	PEGASYS,
T254	tradename 25308 25315	PEGASYS
T255	tradename 25547 25554	PEGASYS
T256	tradename 25700 25707	PEGASYS
T257	co-administereddrug 25735 25744	ribavirin
T258	co-administereddrug 25990 26000	ribavirin,
T259	co-administereddrug 26371 26390	Ribavirin Ribavirin
T260	tradename 26547 26554	PEGASYS
T261	co-administereddrug 26559 26568	ribavirin
T262	co-administereddrug 26590 26599	Ribavirin
T263	co-administereddrug 27030 27039	ribavirin
T264	adversereaction 27056 27082	Neuropsychiatric Reactions
T265	adversereaction 27109 27135	neuropsychiatric reactions
T266	tradename 27188 27195	PEGASYS
T267	adversereaction 27208 27294	suicide, suicidal ideation, homicidal ideation, depression, relapse of drug addiction,
T268	adversereaction 27299 27313	drug overdose.
T269	tradename 27400 27407	PEGASYS
T270	adversereaction 27496 27527	Neuropsychiatric adverse events
T271	adversereaction 27577 27643	aggressive behavior, psychoses, hallucinations, bipolar disorders,
T272	adversereaction 27648 27654	mania.
T273	adversereaction 28060 28140	Cardiovascular Disorders Hypertension, supraventricular arrhythmias, chest pain,
T274	adversereaction 28145 28166	myocardial infarction
T275	tradename 28211 28227	PEGASYS. PEGASYS
T276	tradename 28466 28474	PEGASYS/
T277	co-administereddrug 28474 28483	ribavirin
T278	co-administereddrug 28489 28498	ribavirin
T279	adversereaction 28530 28553	Bone Marrow Suppression
T280	tradename 28554 28561	PEGASYS
T281	adversereaction 28619 28630	cytopenias.
T282	co-administereddrug 28631 28640	Ribavirin
T283	tradename 28727 28735	PEGASYS.
T284	adversereaction 28790 28806	aplastic anemia.
T285	co-administereddrug 28923 28932	ribavirin
T286	tradename 28960 28968	PEGASYS/
T287	co-administereddrug 28968 28977	ribavirin
T288	tradename 29176 29183	PEGASYS
T289	adversereaction 29356 29374	Severe neutropenia
T290	adversereaction 29379 29395	thrombocytopenia
T291	adversereaction 29499 29517	serious infections
T292	adversereaction 29521 29529	bleeding
T293	adversereaction 29562 29574	Pancytopenia
T294	adversereaction 29633 29656	bone marrow suppression
T295	nanoparticle 29763 29784	pegylated interferon/
T296	co-administereddrug 29784 29793	ribavirin
T297	co-administereddrug 29798 29811	azathioprine.
T298	adversereaction 29854 29867	myelotoxicity
T299	co-administereddrug 29965 29977	azathioprine
T300	tradename 30043 30051	PEGASYS,
T301	co-administereddrug 30052 30062	ribavirin,
T302	co-administereddrug 30067 30079	azathioprine
T303	adversereaction 30246 30259	pancytopenia,
T304	nanoparticle 30264 30285	pegylated interferon/
T305	co-administereddrug 30285 30294	ribavirin
T306	adversereaction 30359 30379	Autoimmune Disorders
T307	adversereaction 30411 30431	autoimmune disorders
T308	adversereaction 30442 30606	myositis, hepatitis, thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura, psoriasis, rheumatoid arthritis, interstitial nephritis, thyroiditis,
T309	adversereaction 30611 30639	systemic lupus erythematosus
T310	tradename 30699 30706	PEGASYS
T311	adversereaction 30799 30818	Endocrine Disorders
T312	tradename 30819 30826	PEGASYS
T313	adversereaction 30848 30862	hypothyroidism
T314	adversereaction 30867 30912	hyperthyroidism. Hyperglycemia, hypoglycemia,
T315	adversereaction 30917 30934	diabetes mellitus
T316	tradename 30990 30998	PEGASYS.
T317	tradename 31107 31114	PEGASYS
T318	tradename 31251 31258	PEGASYS
T319	adversereaction 31273 31337	Ophthalmologic Disorders Decrease or loss of vision, retinopathy
T320	adversereaction 31348 31417	macular edema, retinal artery or vein thrombosis, retinal hemorrhages
T321	adversereaction 31422 31468	cotton wool spots, optic neuritis, papilledema
T322	adversereaction 31473 31498	serous retinal detachment
T323	tradename 31543 31550	PEGASYS
T324	tradename 31911 31918	PEGASYS
T325	adversereaction 32024 32097	Cerebrovascular Disorders Ischemic and hemorrhagic cerebrovascular events
T326	activeingredient 32142 32162	interferon alfabased
T327	tradename 32184 32192	PEGASYS.
T328	activeingredient 32427 32448	interferon alfa-based
T329	adversereaction 32528 32543	Hepatic Failure
T330	adversereaction 32548 32571	Hepatitis Exacerbations
T331	indication 32572 32597	Chronic hepatitis C (CHC)
T332	adversereaction 32640 32662	hepatic decompensation
T333	adversereaction 32667 32672	death
T334	tradename 32720 32728	PEGASYS.
T335	indication 32739 32742	CHC
T336	activeingredient 32831 32849	interferon alfa-2a
T337	co-administereddrug 32866 32875	ribavirin
T338	indication 33047 33051	CHC/
T339	tradename 33509 33517	PEGASYS/
T340	co-administereddrug 33517 33526	ribavirin
T341	adversereaction 33642 33668	Exacerbations of hepatitis
T342	indication 33676 33687	hepatitis B
T343	indication 33795 33814	Chronic hepatitis B
T344	adversereaction 33846 33889	acute exacerbations (flares) of hepatitis B
T345	tradename 33972 33979	PEGASYS
T346	tradename 34133 34140	PEGASYS
T347	adversereaction 34180 34205	liver test abnormalities.
T348	tradename 34298 34305	PEGASYS
T349	tradename 34442 34449	PEGASYS
T350	tradename 34686 34693	PEGASYS
T351	adversereaction 34802 34939	Pulmonary Disorders Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis obliterans, interstitial pneumonitis, pulmonary hypertension
T352	adversereaction 34944 34956	sarcoidosis,
T353	adversereaction 34975 34994	respiratory failure
T354	adversereaction 35010 35017	deaths,
T355	tradename 35050 35057	PEGASYS
T356	adversereaction 35101 35120	respiratory failure
T357	tradename 35168 35175	PEGASYS
T358	adversereaction 35242 35263	pulmonary infiltrates
T359	adversereaction 35267 35297	pulmonary function impairment.
T360	adversereaction 35374 35384	Infections
T361	adversereaction 35391 35396	fever
T362	adversereaction 35522 35527	fever
T363	adversereaction 35602 35650	severe infections (bacterial, viral, or fungal),
T364	tradename 35732 35740	PEGASYS.
T365	adversereaction 35885 35937	Colitis Ulcerative and hemorrhagic/ischemic colitis,
T366	adversereaction 36030 36062	Abdominal pain, bloody diarrhea,
T367	adversereaction 36067 36072	fever
T368	adversereaction 36107 36115	colitis.
T369	tradename 36116 36123	PEGASYS
T370	adversereaction 36190 36197	colitis
T371	adversereaction 36281 36307	Pancreatitis Pancreatitis,
T372	co-administereddrug 36366 36375	ribavirin
T373	tradename 36387 36395	PEGASYS/
T374	co-administereddrug 36395 36404	ribavirin
T375	adversereaction 36460 36472	pancreatitis
T376	tradename 36487 36495	PEGASYS/
T377	co-administereddrug 36495 36504	ribavirin
T378	adversereaction 36555 36568	pancreatitis.
T379	adversereaction 36575 36591	Hypersensitivity
T380	adversereaction 36605 36631	hypersensitivity reactions
T381	adversereaction 36639 36682	urticaria, angioedema, bronchoconstriction,
T382	adversereaction 36687 36699	anaphylaxis)
T383	co-administereddrug 36747 36756	ribavirin
T384	tradename 36804 36812	PEGASYS/
T385	co-administereddrug 36812 36821	ribavirin
T386	adversereaction 36901 36923	Serious skin reactions
T387	adversereaction 36934 36960	vesiculobullous eruptions,
T388	adversereaction 36990 37014	Stevens-Johnson Syndrome
T389	adversereaction 37016 37042	erythema multiforme major)
T390	adversereaction 37100 37122	exfoliative dermatitis
T391	adversereaction 37124 37137	erythroderma)
T392	tradename 37179 37186	PEGASYS
T393	co-administereddrug 37204 37214	ribavirin.
T394	adversereaction 37256 37277	severe skin reactions
T395	adversereaction 37340 37356	Impact on Growth
T396	tradename 37430 37437	PEGASYS
T397	co-administereddrug 37443 37452	ribavirin
T398	adversereaction 38060 38103	Peripheral Neuropathy Peripheral neuropathy
T399	co-administereddrug 38176 38188	telbivudine.
T400	adversereaction 38246 38267	peripheral neuropathy
T401	co-administereddrug 38309 38320	telbivudine
T402	tradename 38325 38332	PEGASYS
T403	co-administereddrug 38348 38359	telbivudine
T404	co-administereddrug 38394 38405	telbivudine
T405	indication 38459 38478	chronic hepatitis B
T406	tradename 38732 38739	PEGASYS
T407	tradename 38743 38750	PEGASYS
T408	tradename 39056 39064	PEGASYS/
T409	co-administereddrug 39064 39074	ribavirin.
T410	tradename 39935 39942	PEGASYS
T411	indication 40199 40202	CHC
T412	indication 40797 40800	CHC
T413	indication 40950 40953	CHC
T414	tradename 41093 41100	PEGASYS
T415	dose 41113 41120	180 mcg
T416	co-administereddrug 41164 41171	COPEGUS
T417	tradename 41299 41306	PEGASYS
T418	co-administereddrug 41311 41318	COPEGUS
T419	adversereaction 41327 41379	depression, suicide, relapse of drug abuse/overdose,
T420	adversereaction 41384 41405	bacterial infections,
T421	adversereaction 41453 41484	Hepatic decompensation occurred
T422	indication 41503 41507	CHC/
T423	indication 41899 41910	hepatitis C
T424	indication 41977 41980	CHC
T425	indication 42017 42021	CHC/
T426	tradename 42044 42051	PEGASYS
T427	co-administereddrug 42081 42089	COPEGUS.
T428	indication 42139 42142	CHC
T429	indication 42153 42157	CHC/
T430	adversereaction 42166 42185	bacterial infection
T431	adversereaction 42193 42256	sepsis, osteomyelitis, endocarditis, pyelonephritis, pneumonia)
T432	adversereaction 42323 42350	suicide, suicidal ideation,
T433	adversereaction 42363 42382	anxiety, drug abuse
T434	adversereaction 42387 42508	drug overdose, angina, hepatic dysfunction, fatty liver, cholangitis, arrhythmia, diabetes mellitus, autoimmune phenomena
T435	adversereaction 42516 42613	hyperthyroidism, hypothyroidism, sarcoidosis, systemic lupus erythematosus, rheumatoid arthritis)
T436	adversereaction 42846 43067	neuropathy, aplastic anemia, peptic ulcer, gastrointestinal bleeding, pancreatitis, colitis, corneal ulcer, pulmonary embolism, coma, myositis, cerebral hemorrhage, thrombotic thrombocytopenic purpura, psychotic disorder,
T437	adversereaction 43072 43086	hallucination.
T438	adversereaction 43256 43278	psychiatric reactions,
T439	adversereaction 43289 43333	depression, insomnia, irritability, anxiety,
T440	adversereaction 43338 43355	flu-like symptoms
T441	adversereaction 43364 43400	fatigue, pyrexia, myalgia, headache,
T442	adversereaction 43405 43412	rigors.
T443	adversereaction 43441 43457	anorexia, nausea
T444	adversereaction 43462 43530	vomiting, diarrhea, arthralgias, injection site reactions, alopecia,
T445	adversereaction 43535 43544	pruritus.
T446	tradename 43644 43651	PEGASYS
T447	tradename 43668 43676	PEGASYS/
T448	co-administereddrug 43676 43683	COPEGUS
T449	indication 43737 43740	CHC
T450	tradename 43798 43805	PEGASYS
T451	co-administereddrug 43842 43849	COPEGUS
T452	indication 43879 43883	CHC/
T453	adversereaction 43989 44019	psychiatric, flu-like syndrome
T454	adversereaction 44027 44055	lethargy, fatigue, headache)
T455	adversereaction 44132 44162	thrombocytopenia, neutropenia,
T456	adversereaction 44167 44174	anemia)
T457	indication 44206 44209	CHC
T458	indication 44213 44217	CHC/
T459	tradename 44246 44253	PEGASYS
T460	co-administereddrug 44261 44268	COPEGUS
T461	tradename 44327 44334	PEGASYS
T462	indication 44338 44341	CHC
T463	indication 44346 44350	CHC/
T464	adversereaction 44371 44382	neutropenia
T465	adversereaction 44415 44431	thrombocytopenia
T466	co-administereddrug 44507 44514	COPEGUS
T467	indication 44518 44521	CHC
T468	indication 44526 44530	CHC/
T469	adversereaction 44547 44553	anemia
T470	tradename 44583 44590	PEGASYS
T471	dose 44637 44644	1000 mg
T472	dose 44648 44655	1200 mg
T473	co-administereddrug 44656 44663	COPEGUS
T474	dose 44709 44715	800 mg
T475	co-administereddrug 44716 44723	COPEGUS
T476	co-administereddrug 44738 44745	COPEGUS
T477	dose 44792 44799	1000 mg
T478	dose 44803 44810	1200 mg
T479	co-administereddrug 44811 44818	COPEGUS
T480	dose 44865 44871	800 mg
T481	co-administereddrug 44872 44879	COPEGUS
T482	indication 44895 44914	Chronic hepatitis C
T483	tradename 44963 44970	PEGASYS
T484	dose 44975 44981	800 mg
T485	co-administereddrug 44982 44989	COPEGUS
T486	tradename 45128 45135	PEGASYS
T487	co-administereddrug 45154 45161	COPEGUS
T488	tradename 45269 45276	PEGASYS
T489	dose 45281 45288	1000 mg
T490	dose 45292 45299	1200 mg
T491	co-administereddrug 45300 45308	COPEGUS.
T492	indication 45488 45507	Chronic Hepatitis C
T493	indication 45563 45566	CHC
T494	indication 45601 45604	CHC
T495	tradename 45648 45655	PEGASYS
T496	dose 45656 45663	180 mcg
T497	dose 45698 45704	3 MIU*
T498	dose 45708 45716	6/3 MIU*
T499	tradename 45747 45754	PEGASYS
T500	dose 45755 45762	180 mcg
T501	dose 45765 45772	1000 mg
T502	dose 45776 45783	1200 mg
T503	co-administereddrug 45784 45791	COPEGUS
T504	dose 45814 45821	1000 mg
T505	dose 45825 45832	1200 mg
T506	adversereaction 45916 45939	Injection site reaction
T507	adversereaction 45953 45988	Endocrine Disorders Hypothyroidism
T508	adversereaction 45998 46015	Flu-like Symptoms
T509	indication 46292 46295	CHC
T510	indication 46330 46333	CHC
T511	tradename 46377 46384	PEGASYS
T512	dose 46385 46392	180 mcg
T513	dose 46427 46433	3 MIU*
T514	dose 46437 46445	6/3 MIU*
T515	tradename 46476 46483	PEGASYS
T516	dose 46484 46491	180 mcg
T517	dose 46494 46501	1000 mg
T518	dose 46505 46512	1200 mg
T519	co-administereddrug 46513 46520	COPEGUS
T520	dose 46543 46550	1000 mg
T521	dose 46554 46561	1200 mg
T522	adversereaction 46617 46633	Fatigue/Asthenia
T523	adversereaction 46647 46654	Pyrexia
T524	adversereaction 46668 46674	Rigors
T525	adversereaction 46688 46692	Pain
T526	adversereaction 46722 46737	Nausea/Vomiting
T527	adversereaction 46750 46758	Diarrhea
T528	adversereaction 46771 46785	Abdominal pain
T529	adversereaction 46796 46805	Dry mouth
T530	adversereaction 46814 46823	Dyspepsia
T531	adversereaction 46858 46869	Lymphopenia
T532	adversereaction 46881 46887	Anemia
T533	adversereaction 46899 46910	Neutropenia
T534	adversereaction 46922 46938	Thrombocytopenia
T535	adversereaction 46979 47004	Anorexia Weight decrease
T536	adversereaction 47081 47088	Myalgia
T537	adversereaction 47102 47112	Arthralgia
T538	adversereaction 47126 47135	Back pain
T539	adversereaction 47160 47168	Headache
T540	adversereaction 47182 47191	Dizziness
T541	adversereaction 47225 47242	Memory impairment
T542	indication 47559 47562	CHC
T543	indication 47597 47600	CHC
T544	tradename 47644 47651	PEGASYS
T545	dose 47652 47659	180 mcg
T546	dose 47694 47700	3 MIU*
T547	dose 47704 47712	6/3 MIU*
T548	tradename 47743 47750	PEGASYS
T549	dose 47751 47758	180 mcg
T550	dose 47761 47768	1000 mg
T551	dose 47772 47779	1200 mg
T552	co-administereddrug 47780 47787	COPEGUS
T553	dose 47810 47817	1000 mg
T554	dose 47821 47828	1200 mg
T555	adversereaction 47896 47929	Irritability/Anxiety/ Nervousness
T556	adversereaction 47944 47952	Insomnia
T557	adversereaction 47965 47975	Depression
T558	adversereaction 47988 48012	Concentration impairment
T559	adversereaction 48024 48039	Mood alteration
T560	adversereaction 48088 48095	Dyspnea
T561	adversereaction 48107 48112	Cough
T562	adversereaction 48123 48141	Dyspnea exertional
T563	adversereaction 48189 48197	Alopecia
T564	adversereaction 48211 48219	Pruritus
T565	adversereaction 48232 48242	Dermatitis
T566	adversereaction 48254 48262	Dry skin
T567	adversereaction 48274 48278	Rash
T568	adversereaction 48288 48306	Sweating increased
T569	adversereaction 48316 48322	Eczema
T570	adversereaction 48350 48364	Vision blurred
T571	dose 48395 48430	6 million international units (MIU)
T572	frequency 48431 48472	three times a week for the first 12 weeks
T573	dose 48485 48514	3 million international units
T574	frequency 48515 48546	three times a week for 36 weeks
T575	routeofadministration 48553 48568	subcutaneously.
T576	tradename 48902 48909	PEGASYS
T577	co-administereddrug 48939 48947	COPEGUS,
T578	tradename 49501 49508	PEGASYS
T579	co-administereddrug 49513 49520	COPEGUS
T580	adversereaction 49526 49548	influenza-like illness
T581	adversereaction 49556 49589	upper respiratory tract infection
T582	adversereaction 49597 49605	headache
T583	adversereaction 49613 49638	gastrointestinal disorder
T584	adversereaction 49646 49659	skin disorder
T585	adversereaction 49671 49694	injection-site reaction
T586	tradename 49739 49746	PEGASYS
T587	co-administereddrug 49751 49758	COPEGUS
T588	adversereaction 49823 49947	depression, psychiatric evaluation abnormal, transient blindness, retinal exudates, hyperglycemia, type 1 diabetes mellitus,
T589	adversereaction 49952 49959	anemia)
T590	tradename 50102 50109	PEGASYS
T591	co-administereddrug 50115 50122	COPEGUS
T592	adversereaction 50150 50163	hyperglycemia
T593	adversereaction 50168 50184	cholecystectomy)
T594	tradename 50372 50379	PEGASYS
T595	dose 50380 50394	180 mcg/1.73 m
T596	co-administereddrug 50403 50410	COPEGUS
T597	dose 50411 50419	15 mg/kg
T598	tradename 50428 50435	PEGASYS
T599	dose 50436 50450	180 mcg/1.73 m
T600	adversereaction 50535 50557	Influenza like illness
T601	adversereaction 50564 50587	Injection site reaction
T602	adversereaction 50594 50601	Fatigue
T603	adversereaction 50608 50620	Irritability
T604	adversereaction 50655 50680	Gastrointestinal disorder
T605	adversereaction 50713 50721	Headache
T606	adversereaction 50768 50772	Rash
T607	adversereaction 50779 50787	Pruritus
T608	adversereaction 50849 50869	Musculoskeletal pain
T609	adversereaction 50899 50907	Insomnia
T610	adversereaction 50949 50967	Decreased appetite
T611	tradename 51151 51158	PEGASYS
T612	adversereaction 51779 51796	Growth inhibition
T613	tradename 51891 51898	PEGASYS
T614	co-administereddrug 51904 51913	ribavirin
T615	indication 53349 53352	CHC
T616	tradename 53448 53456	PEGASYS/
T617	co-administereddrug 53456 53463	COPEGUS
T618	adversereaction 53620 53631	neutropenia
T619	adversereaction 53639 53645	anemia
T620	adversereaction 53653 53669	thrombocytopenia
T621	adversereaction 53676 53691	weight decrease
T622	adversereaction 53703 53718	mood alteration
T623	indication 53726 53745	Chronic Hepatitis B
T624	tradename 53828 53835	PEGASYS
T625	indication 53839 53858	chronic hepatitis B
T626	indication 53887 53890	CHC
T627	tradename 53891 53898	PEGASYS
T628	adversereaction 53927 53953	exacerbations of hepatitis
T629	tradename 54007 54014	PEGASYS
T630	indication 54039 54050	hepatitis B
T631	indication 54240 54251	hepatitis B
T632	adversereaction 54265 54275	infections
T633	adversereaction 54277 54323	sepsis, appendicitis, tuberculosis, influenza)
T634	adversereaction 54325 54344	hepatitis B flares,
T635	adversereaction 54349 54385	thrombotic thrombocytopenic purpura.
T636	adversereaction 54419 54437	anaphylactic shock
T637	tradename 54542 54550	PEGASYS.
T638	tradename 54604 54611	PEGASYS
T639	adversereaction 54654 54661	pyrexia
T640	adversereaction 54676 54684	headache
T641	adversereaction 54699 54706	fatigue
T642	adversereaction 54722 54729	myalgia
T643	adversereaction 54744 54752	alopecia
T644	adversereaction 54771 54779	anorexia
T645	indication 54809 54820	hepatitis B
T646	tradename 54843 54850	PEGASYS
T647	tradename 54904 54911	PEGASYS
T648	tradename 54985 54992	PEGASYS
T649	adversereaction 55044 55055	neutropenia
T650	adversereaction 55063 55079	thrombocytopenia
T651	adversereaction 55091 55104	ALT elevation
T652	indication 55190 55201	hepatitis B
T653	tradename 55270 55277	PEGASYS
T654	indication 55290 55293	CHC
T655	indication 55322 55333	hepatitis C
T656	tradename 55436 55443	PEGASYS
T657	co-administereddrug 55480 55488	COPEGUS.
T658	adversereaction 55525 55536	neutropenia
T659	indication 55585 55588	CHC
T660	indication 55609 55613	CHC/
T661	tradename 55636 55643	PEGASYS
T662	co-administereddrug 55680 55688	COPEGUS.
T663	tradename 55705 55712	PEGASYS
T664	adversereaction 55722 55733	neutropenia
T665	tradename 55772 55779	PEGASYS
T666	tradename 55822 55830	PEGASYS/
T667	co-administereddrug 55830 55837	COPEGUS
T668	indication 55866 55870	CHC/
T669	adversereaction 55934 55946	neutropenia.
T670	indication 55976 55979	CHC
T671	indication 56005 56009	CHC/
T672	tradename 56046 56053	PEGASYS
T673	tradename 56329 56336	PEGASYS
T674	co-administereddrug 56342 56349	COPEGUS
T675	indication 56431 56434	CHC
T676	indication 56446 56450	CHC/
T677	indication 56498 56501	CHC
T678	indication 56523 56527	CHC/
T679	indication 56540 56551	hepatitis C
T680	adversereaction 56738 56749	lymphopenia
T681	tradename 56822 56829	PEGASYS
T682	co-administereddrug 56834 56841	COPEGUS
T683	adversereaction 56856 56867	lymphopenia
T684	tradename 56978 56985	PEGASYS
T685	co-administereddrug 56990 56997	COPEGUS
T686	indication 57129 57132	CHC
T687	tradename 57320 57327	PEGASYS
T688	co-administereddrug 57333 57340	COPEGUS
T689	indication 57540 57551	hepatitis C
T690	indication 57597 57600	CHC
T691	indication 57621 57625	CHC/
T692	tradename 57651 57658	PEGASYS
T693	indication 57740 57743	CHC
T694	indication 57764 57768	CHC/
T695	co-administereddrug 57816 57823	COPEGUS
T696	adversereaction 57883 57899	thrombocytopenia
T697	indication 57951 57954	CHC
T698	indication 57965 57969	CHC/
T699	indication 58096 58107	hepatitis C
T700	adversereaction 58310 58316	anemia
T701	indication 58423 58426	CHC
T702	indication 58446 58450	CHC/
T703	tradename 58473 58480	PEGASYS
T704	adversereaction 58516 58522	anemia
T705	co-administereddrug 58526 58533	COPEGUS
T706	indication 58585 58588	CHC
T707	indication 58609 58613	CHC/
T708	tradename 58856 58863	PEGASYS
T709	co-administereddrug 58893 58901	COPEGUS.
T710	indication 58981 58984	CHC
T711	indication 59074 59077	CHC
T712	tradename 59240 59247	PEGASYS
T713	co-administereddrug 59277 59285	COPEGUS.
T714	indication 59402 59421	Chronic Hepatitis C
T715	indication 59453 59464	hepatitis C
T716	adversereaction 59659 59677	hyperbilirubinemia
T717	adversereaction 59752 59785	Liver function test abnormalities
T718	adversereaction 59839 59860	autoimmune hepatitis,
T719	indication 59957 59976	Chronic Hepatitis B
T720	adversereaction 59977 60001	Transient ALT elevations
T721	indication 60020 60031	hepatitis B
T722	tradename 60045 60053	PEGASYS.
T723	tradename 61049 61056	PEGASYS
T724	tradename 61086 61093	PEGASYS
T725	co-administereddrug 61123 61130	COPEGUS
T726	indication 61268 61279	hepatitis C
T727	tradename 61408 61415	PEGASYS
T728	tradename 61450 61457	PEGASYS
T729	co-administereddrug 61462 61469	COPEGUS
T730	tradename 61582 61589	PEGASYS
T731	tradename 62183 62190	PEGASYS
T732	dose 62191 62205	180 mcg/1.73 m
T733	co-administereddrug 62214 62221	COPEGUS
T734	dose 62222 62230	15 mg/kg
T735	tradename 62239 62246	PEGASYS
T736	dose 62247 62261	180 mcg/1.73 m
T737	tradename 62287 62294	PEGASYS
T738	indication 62933 62952	Chronic Hepatitis C
T739	tradename 63000 63007	PEGASYS
T740	co-administereddrug 63024 63031	COPEGUS
T741	activeingredient 63064 63083	interferon alfa-2a,
T742	tradename 63160 63167	PEGASYS
T743	co-administereddrug 63184 63192	COPEGUS,
T744	indication 63289 63308	Chronic Hepatitis B
T745	indication 63341 63352	hepatitis B
T746	tradename 63375 63382	PEGASYS
T747	activeingredient 63428 63447	interferon alfa-2a,
T748	tradename 63527 63534	PEGASYS
T749	tradename 64402 64409	PEGASYS
T750	tradename 64604 64611	PEGASYS
T751	adversereaction 64862 64883	pure red cell aplasia
T752	adversereaction 64914 64946	hearing impairment, hearing loss
T753	adversereaction 64976 64995	tongue pigmentation
T754	adversereaction 65022 65043	Liver graft rejection
T755	adversereaction 65048 65069	renal graft rejection
T756	adversereaction 65147 65158	dehydration
T757	adversereaction 65200 65222	serious skin reactions
T758	adversereaction 65238 65246	seizures
T759	tradename 65447 65454	PEGASYS
T760	tradename 65618 65625	PEGASYS
T761	tradename 65887 65895	PEGASYS.
T762	co-administereddrug 65901 65910	Methadone
T763	co-administereddrug 65965 65975	methadone,
T764	tradename 65991 65998	PEGASYS
T765	co-administereddrug 66228 66237	methadone
T766	co-administereddrug 66303 66312	methadone
T767	tradename 66317 66324	PEGASYS
T768	tradename 66346 66353	PEGASYS
T769	indication 66359 66378	chronic hepatitis C
T770	dose 66427 66434	180 mcg
T771	tradename 66435 66442	PEGASYS
T772	routeofadministration 66443 66457	subcutaneously
T773	co-administereddrug 66494 66503	methadone
T774	dose 66537 66543	95 mg,
T775	dose 66550 66566	30 mg to 150 mg)
T776	tradename 66586 66594	PEGASYS.
T777	co-administereddrug 66600 66609	methadone
T778	tradename 66664 66671	PEGASYS
T779	co-administereddrug 66707 66716	Methadone
T780	tradename 66755 66762	PEGASYS
T781	indication 66794 66813	chronic hepatitis C
T782	co-administereddrug 66837 66847	methadone.
T783	indication 67061 67065	CHC/
T784	tradename 67232 67240	PEGASYS/
T785	co-administereddrug 67240 67249	ribavirin
T786	tradename 67571 67579	PEGASYS,
T787	co-administereddrug 67580 67589	ribavirin
T788	co-administereddrug 67743 67753	Zidovudine
T789	co-administereddrug 67797 67807	zidovudine
T790	tradename 67828 67836	PEGASYS/
T791	co-administereddrug 67836 67843	COPEGUS
T792	adversereaction 67861 67872	neutropenia
T793	adversereaction 67914 67920	anemia
T794	co-administereddrug 68003 68013	zidovudine
T795	adversereaction 68015 68026	neutropenia
T796	adversereaction 68040 68046	anemia
T797	co-administereddrug 68078 68088	zidovudine
T798	tradename 68173 68181	PEGASYS,
T799	co-administereddrug 68182 68191	ribavirin
T800	adversereaction 68283 68305	hepatic decompensation
T801	tradename 68437 68444	PEGASYS
T802	tradename 68559 68566	PEGASYS
T803	tradename 68579 68586	PEGASYS
T804	activeingredient 68650 68668	interferon alfa-2a
T805	tradename 68893 68900	PEGASYS
T806	tradename 69005 69012	PEGASYS
T807	tradename 69032 69039	PEGASYS
T808	tradename 69144 69151	PEGASYS
T809	co-administereddrug 69307 69316	Ribavirin
T810	co-administereddrug 69452 69472	ribavirin. Ribavirin
T811	co-administereddrug 69641 69650	ribavirin
T812	co-administereddrug 69663 69672	Ribavirin
T813	co-administereddrug 69695 69704	Ribavirin
T814	co-administereddrug 69866 69875	ribavirin
T815	tradename 70405 70413	PEGASYS.
T816	tradename 70465 70473	PEGASYS,
T817	tradename 70726 70733	PEGASYS
T818	inactiveingredient 70743 70758	benzyl alcohol.
T819	inactiveingredient 70784 70798	benzyl alcohol
T820	tradename 71095 71102	PEGASYS
T821	co-administereddrug 71132 71139	COPEGUS
T822	adversereaction 71328 71379	CNS, cardiac, and systemic (e.g., flu-like) effects
T823	tradename 71460 71467	PEGASYS
T824	tradename 71488 71495	PEGASYS
T825	tradename 71790 71797	PEGASYS
T826	tradename 71909 71916	PEGASYS
T827	indication 72095 72120	Chronic hepatitis C (CHC)
T828	adversereaction 72163 72185	hepatic decompensation
T829	tradename 72243 72251	PEGASYS.
T830	tradename 72350 72357	PEGASYS
T831	indication 72508 72527	Chronic hepatitis B
T832	adversereaction 72549 72602	transient acute exacerbations (flares) of hepatitis B
T833	tradename 72685 72692	PEGASYS
T834	tradename 72906 72913	PEGASYS
T835	tradename 73007 73014	PEGASYS
T836	co-administereddrug 73019 73026	COPEGUS
T837	indication 73033 73036	CHC
T838	tradename 73286 73293	PEGASYS
T839	dose 73324 73331	135 mcg
T840	frequency 73332 73344	once weekly.
T841	tradename 73392 73399	PEGASYS
T842	tradename 73408 73423	PEGASYS-related
T843	adversereaction 73450 73457	anemia)
T844	tradename 73559 73566	PEGASYS
T845	tradename 73574 73589	PEGASYS-related
T846	tradename 73653 73660	PEGASYS
T847	tradename 73748 73755	PEGASYS
T848	dose 73756 73763	180 mcg
T849	frequency 73764 73776	once weekly.
T850	tradename 73777 73784	PEGASYS
T851	tradename 74123 74131	PEGASYS.
T852	tradename 74689 74696	PEGASYS
T853	tradename 74959 74966	PEGASYS
T854	tradename 75142 75150	PEGASYS.
T855	indication 75156 75175	Chronic Hepatitis B
T856	tradename 75203 75210	PEGASYS
T857	indication 75252 75263	Hepatitis B
T858	indication 75310 75321	Hepatitis C
T859	tradename 75556 75563	PEGASYS
T860	dose 75565 75572	180 mcg
T861	frequency 75572 75588	/day for 7 days)
T862	frequency 75649 75655	Weekly
T863	dose 75671 75678	630 mcg
T864	adversereaction 75757 75802	fatigue, elevated liver enzymes, neutropenia,
T865	adversereaction 75807 75824	thrombocytopenia.
T866	tradename 75859 75867	PEGASYS.
T867	tradename 75940 75948	PEGASYS,
T868	nanoparticle 75949 75971	peginterferon alfa-2a,
T869	activeingredient 75999 76029	recombinant alfa-2a interferon
T870	molecularweight 76065 76080	20,000 daltons)
T871	surfacecoating 76104 76145	bis-monomethoxy polyethylene glycol (PEG)
T872	molecularweight 76168 76183	40,000 daltons)
T873	surfacecoating 76189 76192	PEG
T874	activeingredient 76234 76249	interferon alfa
T875	nanoparticle 76292 76313	Peginterferon alfa-2a
T876	molecularweight 76353 76368	60,000 daltons.
T877	activeingredient 76369 76387	Interferon alfa-2a
T878	tradename 76536 76543	PEGASYS
T879	routeofadministration 76636 76651	subcutaneously.
T880	dose 76666 76674	180 mcg/
T881	nanoparticle 76677 76698	peginterferon alfa-2a
T882	activeingredient 76727 76746	interferon alfa-2a)
T883	inactiveingredient 76761 76772	acetic acid
T884	inactiveingredient 76784 76798	benzyl alcohol
T885	inactiveingredient 76808 76822	polysorbate 80
T886	inactiveingredient 76834 76859	sodium acetate trihydrate
T887	inactiveingredient 76875 76890	sodium chloride
T888	nanoparticle 76954 76975	peginterferon alfa-2a
T889	activeingredient 77004 77023	interferon alfa-2a)
T890	inactiveingredient 77038 77049	acetic acid
T891	inactiveingredient 77063 77077	benzyl alcohol
T892	inactiveingredient 77086 77100	polysorbate 80
T893	inactiveingredient 77113 77138	sodium acetate trihydrate
T894	inactiveingredient 77156 77171	sodium chloride
T895	dose 77223 77231	180 mcg/
T896	nanoparticle 77238 77258	peginteferon alfa-2a
T897	activeingredient 77287 77305	interferon alfa2a)
T898	inactiveingredient 77321 77332	acetic acid
T899	inactiveingredient 77346 77360	benzyl alcohol
T900	inactiveingredient 77369 77383	polysorbate 80
T901	inactiveingredient 77396 77421	sodium acetate trihydrate
T902	inactiveingredient 77439 77454	sodium chloride
T903	nanoparticle 77521 77541	peginteferon alfa-2a
T904	activeingredient 77570 77588	interferon alfa2a)
T905	inactiveingredient 77604 77615	acetic acid
T906	inactiveingredient 77629 77645	benzyl alcohol (
T907	inactiveingredient 77652 77666	polysorbate 80
T908	inactiveingredient 77679 77704	sodium acetate trihydrate
T909	inactiveingredient 77722 77737	sodium chloride
T910	dose 77900 77915	180 or 135 mcg)
T911	routeofadministration 78076 78088	subcutaneous
T912	nanoparticle 78308 78354	Pegylated recombinant human interferon alfa-2a
T913	tradename 78459 78466	PEGASYS
T914	dose 78716 78729	90 to 270 mcg
T915	tradename 78733 78741	PEGASYS.
T916	tmax 78792 78806	72 to 96 hours
T917	frequency 79060 79071	once weekly
T918	tradename 79190 79197	PEGASYS
T919	clearance 79202 79210	94 mL/h,
T920	activeingredient 79263 79281	interferon alfa-2a
T921	routeofadministration 79329 79341	subcutaneous
T922	indication 79366 79385	chronic hepatitis C
T923	plasmahalflife 79390 79399	160 hours
T924	plasmahalflife 79407 79423	84 to 353 hours)
T925	plasmahalflife 79436 79443	5 hours
T926	plasmahalflife 79451 79468	3.7 to 8.5 hours)
T927	tradename 79520 79527	PEGASYS
T928	auc 79640 79659	1295 to 1663 ngh/mL
T929	dose 79699 79706	180 mcg
T930	tradename 79707 79715	PEGASYS,
T931	cmax 79754 79769	9 vs. 10 ng/mL)
T932	indication 79909 79912	CHC
T933	tradename 79922 79929	PEGASYS
T934	dose 79983 79999	180 mcg/1.73 m2)
T935	tradename 80018 80025	PEGASYS
T936	dose 80231 80238	180 mcg
T937	dose 80565 80572	180 mcg
T938	indication 80635 80638	CHC
T939	tradename 80899 80906	PEGASYS
T940	dose 80907 80914	180 mcg
T941	frequency 80915 80926	once weekly
T942	nanoparticle 80950 80971	peginterferon alfa-2a
T943	tradename 81114 81122	PEGASYS.
T944	tradename 81126 81133	PEGASYS
T945	nanoparticle 81335 81356	peginterferon alfa-2a
T946	dose 81460 81467	135 mcg
T947	frequency 81468 81479	once weekly
T948	tradename 81480 81487	PEGASYS
T949	nanoparticle 81580 81600	peginterferon alfa2a
T950	dose 82007 82013	90 mcg
T951	frequency 82014 82025	once weekly
T952	tradename 82166 82173	PEGASYS
T953	dose 82204 82211	135 mcg
T954	frequency 82212 82224	once weekly.
T955	nanoparticle 82251 82272	peginterferon alfa-2a
T956	nanoparticle 82381 82402	peginterferon alfa-2a
T957	dose 82412 82419	135 mcg
T958	tradename 82503 82510	PEGASYS
T959	dose 82546 82553	135 mcg
T960	frequency 82554 82565	once weekly
T961	dose 82788 82794	90 mcg
T962	frequency 82795 82806	once weekly
T963	tradename 82965 82972	PEGASYS
T964	activeingredient 82993 83032	recombinant human interferon &#x3b1;-2a
T965	nanoparticle 83041 83065	Peginterferon &#x3b1;-2a
T966	activeingredient 83324 83346	interferon &#x3b1;-2a,
T967	nanoparticle 83440 83464	peginterferon &#x3b1;-2a
T968	nanoparticle 83625 83643	PEG-IFN &#x3b1;-2a
T969	nanoparticle 83729 83747	PEG-IFN &#x3b1;-2a
T970	co-administereddrug 83752 83761	ribavirin
T971	nanoparticle 83939 83954	PEG-IFN-&#x3b1;
T972	co-administereddrug 83959 83968	ribavirin
T973	activeingredient 84125 84136	IFN-&#x3b1;
T974	co-administereddrug 84141 84150	ribavirin
T975	tradename 84275 84282	PEGASYS
T976	tradename 84464 84471	PEGASYS
T977	tradename 84509 84516	PEGASYS
T978	tradename 84857 84864	PEGASYS
T979	tradename 84916 84923	PEGASYS
T980	routeofadministration 85049 85061	subcutaneous
T981	dose 85076 85087	600 mcg/kg/
T982	dose 85093 85105	7200 mcg/m2/
T983	tradename 85296 85303	PEGASYS
T984	frequency 85304 85334	every other day for one month,
T985	tradename 85599 85606	PEGASYS
T986	frequency 85695 85710	Every other day
T987	dose 85723 85733	100 mcg/kg
T988	dose 85735 85747	1200 mcg/m2)
T989	tradename 85748 85755	PEGASYS
T990	tradename 85903 85910	PEGASYS
T991	activeingredient 86057 86075	interferon alfa-2a
T992	dose 86104 86118	25 x 106 IU/kg
T993	frequency 86118 86123	/day.
T994	tradename 86256 86263	PEGASYS
T995	indication 86316 86335	Chronic Hepatitis C
T996	tradename 86357 86365	PEGASYS/
T997	co-administereddrug 86365 86372	COPEGUS
T998	tradename 86440 86447	PEGASYS
T999	co-administereddrug 86468 86475	COPEGUS
T1000	indication 86497 86508	hepatitis C
T1001	tradename 86977 86984	PEGASYS
T1002	dose 86985 86992	180 mcg
T1003	routeofadministration 86993 87005	subcutaneous
T1004	frequency 87006 87017	once weekly
T1005	routeofadministration 87026 87030	oral
T1006	tradename 87040 87047	PEGASYS
T1007	dose 87048 87055	180 mcg
T1008	frequency 87056 87067	once weekly
T1009	co-administereddrug 87073 87080	COPEGUS
T1010	dose 87081 87088	1000 mg
T1011	routeofadministration 87089 87097	by mouth
T1012	dose 87131 87138	1200 mg
T1013	routeofadministration 87139 87147	by mouth
T1014	dose 87225 87230	3 MIU
T1015	routeofadministration 87231 87243	subcutaneous
T1016	frequency 87244 87262	three times a week
T1017	co-administereddrug 87268 87277	ribavirin
T1018	dose 87278 87285	1000 mg
T1019	dose 87289 87296	1200 mg
T1020	routeofadministration 87297 87306	by mouth)
T1021	co-administereddrug 87400 87407	COPEGUS
T1022	tradename 87568 87575	PEGASYS
T1023	co-administereddrug 87596 87603	COPEGUS
T1024	tradename 87641 87648	PEGASYS
T1025	co-administereddrug 87681 87690	ribavirin
T1026	co-administereddrug 87904 87913	Ribavirin
T1027	dose 87914 87921	1000 mg
T1028	dose 87925 87932	1200 mg
T1029	tradename 87934 87941	PEGASYS
T1030	tradename 87953 87960	PEGASYS
T1031	co-administereddrug 87963 87970	COPEGUS
T1032	dose 87971 87978	1000 mg
T1033	dose 87982 87989	1200 mg
T1034	tradename 88198 88206	PEGASYS/
T1035	co-administereddrug 88206 88213	COPEGUS
T1036	co-administereddrug 88250 88260	ribavirin)
T1037	tradename 88338 88345	PEGASYS
T1038	dose 88346 88353	180 mcg
T1039	routeofadministration 88354 88366	subcutaneous
T1040	frequency 88367 88378	once weekly
T1041	co-administereddrug 88447 88454	COPEGUS
T1042	dose 88470 88476	800 mg
T1043	dose 88480 88495	1000 mg/1200 mg
T1044	tradename 89151 89158	PEGASYS
T1045	dose 89163 89170	1000 mg
T1046	dose 89174 89181	1200 mg
T1047	co-administereddrug 89185 89192	COPEGUS
T1048	dose 89356 89362	800 mg
T1049	co-administereddrug 89363 89371	COPEGUS.
T1050	tradename 89468 89475	PEGASYS
T1051	dose 89480 89486	800 mg
T1052	co-administereddrug 89490 89497	COPEGUS
T1053	dose 89571 89578	1000 mg
T1054	dose 89582 89589	1200 mg
T1055	co-administereddrug 89593 89600	COPEGUS
T1056	tradename 89822 89829	PEGASYS
T1057	co-administereddrug 89832 89839	COPEGUS
T1058	dose 89840 89846	800 mg
T1059	tradename 89856 89863	PEGASYS
T1060	co-administereddrug 89866 89873	COPEGUS
T1061	dose 89874 89881	1000 mg
T1062	dose 89885 89893	1200 mg*
T1063	tradename 89903 89910	PEGASYS
T1064	co-administereddrug 89913 89920	COPEGUS
T1065	dose 89921 89927	800 mg
T1066	tradename 89937 89944	PEGASYS
T1067	co-administereddrug 89947 89954	COPEGUS
T1068	dose 89955 89962	1000 mg
T1069	dose 89966 89974	1200 mg*
T1070	dose 90168 90175	1000 mg
T1071	dose 90209 90216	1200 mg
T1072	nanoparticle 90388 90414	pegylated interferon alpha
T1073	indication 91573 91593	chronic hepatitis C,
T1074	co-administereddrug 91661 91668	COPEGUS
T1075	dose 91683 91691	15 mg/kg
T1076	frequency 91691 91695	/day
T1077	tradename 91701 91708	PEGASYS
T1078	dose 91709 91724	180 mcg/1.73 m2
T1079	frequency 91745 91756	once weekly
T1080	co-administereddrug 92031 92038	COPEGUS
T1081	tradename 92044 92051	PEGASYS
T1082	tradename 92055 92062	PEGASYS
T1083	tradename 92093 92100	PEGASYS
T1084	co-administereddrug 92159 92166	COPEGUS
T1085	tradename 92172 92180	PEGASYS.
T1086	co-administereddrug 92303 92310	COPEGUS
T1087	tradename 92316 92323	PEGASYS
T1088	tradename 92340 92347	PEGASYS
T1089	tradename 92618 92634	PEGASYS PEGASYS
T1090	dose 92637 92651	180 mcg/1.73 m
T1091	dose 92662 92676	180 mcg/1.73 m
T1092	co-administereddrug 92696 92703	COPEGUS
T1093	dose 92704 92712	15 mg/kg
T1094	indication 93311 93330	Chronic Hepatitis C
T1095	tradename 93376 93383	PEGASYS
T1096	tradename 93400 93408	PEGASYS/
T1097	co-administereddrug 93408 93415	COPEGUS
T1098	indication 93463 93467	CHC/
T1099	tradename 93505 93512	PEGASYS
T1100	dose 93513 93520	180 mcg
T1101	routeofadministration 93521 93533	subcutaneous
T1102	routeofadministration 93554 93558	oral
T1103	tradename 93568 93575	PEGASYS
T1104	dose 93576 93583	180 mcg
T1105	frequency 93584 93595	once weekly
T1106	co-administereddrug 93601 93608	COPEGUS
T1107	dose 93609 93615	800 mg
T1108	routeofadministration 93616 93624	by mouth
T1109	frequency 93625 93630	daily
T1110	activeingredient 93645 93664	interferon alfa-2a)
T1111	dose 93666 93671	3 MIU
T1112	routeofadministration 93672 93684	subcutaneous
T1113	frequency 93685 93703	three times a week
T1114	co-administereddrug 93709 93716	COPEGUS
T1115	dose 93717 93723	800 mg
T1116	routeofadministration 93724 93732	by mouth
T1117	frequency 93733 93739	daily.
T1118	co-administereddrug 93875 93882	COPEGUS
T1119	tradename 93934 93941	PEGASYS
T1120	indication 94071 94091	chronic hepatitis C,
T1121	indication 94511 94530	Chronic Hepatitis C
T1122	co-administereddrug 94574 94581	COPEGUS
T1123	dose 94582 94588	800 mg
T1124	tradename 94598 94605	PEGASYS
T1125	tradename 94625 94632	PEGASYS
T1126	co-administereddrug 94635 94642	COPEGUS
T1127	dose 94643 94649	800 mg
T1128	indication 94841 94845	CHC/
T1129	nanoparticle 94975 95001	pegylated interferon alpha
T1130	tradename 95324 95331	PEGASYS
T1131	co-administereddrug 95336 95345	ribavirin
T1132	indication 95398 95401	CHC
T1133	tradename 95457 95464	PEGASYS
T1134	co-administereddrug 95494 95503	ribavirin
T1135	indication 95629 95648	Chronic Hepatitis C
T1136	tradename 95670 95677	PEGASYS
T1137	tradename 95722 95729	PEGASYS
T1138	indication 95751 95762	hepatitis C
T1139	routeofadministration 96080 96092	subcutaneous
T1140	activeingredient 96715 96734	interferon alfa-2a)
T1141	dose 96735 96740	3 MIU
T1142	frequency 96741 96760	three times a week,
T1143	tradename 96761 96768	PEGASYS
T1144	dose 96769 96776	135 mcg
T1145	frequency 96777 96788	once weekly
T1146	tradename 96792 96799	PEGASYS
T1147	dose 96800 96807	180 mcg
T1148	frequency 96808 96820	once weekly.
T1149	dose 96876 96881	6 MIU
T1150	frequency 96882 96913	three times a week for 12 weeks
T1151	dose 96926 96931	3 MIU
T1152	frequency 96932 96963	three times a week for 36 weeks
T1153	tradename 96967 96974	PEGASYS
T1154	dose 96975 96982	180 mcg
T1155	frequency 96983 96995	once weekly.
T1156	dose 97044 97049	3 MIU
T1157	frequency 97050 97069	three times a week,
T1158	tradename 97070 97077	PEGASYS
T1159	dose 97078 97084	90 mcg
T1160	frequency 97085 97096	once weekly
T1161	tradename 97100 97107	PEGASYS
T1162	dose 97108 97115	180 mcg
T1163	frequency 97116 97131	once each week.
T1164	tradename 97170 97177	PEGASYS
T1165	dose 97178 97185	180 mcg
T1166	tradename 97477 97484	PEGASYS
T1167	dose 97485 97492	135 mcg
T1168	dose 97528 97536	180 mcg.
T1169	tradename 97561 97568	PEGASYS
T1170	dose 97569 97575	90 mcg
T1171	tradename 97601 97608	PEGASYS
T1172	dose 97609 97616	180 mcg
T1173	dose 97720 97725	3 MIU
T1174	tradename 97735 97742	PEGASYS
T1175	dose 97743 97750	180 mcg
T1176	dose 97786 97801	6/3 MIU&#x20ac;
T1177	tradename 97811 97818	PEGASYS
T1178	dose 97819 97826	180 mcg
T1179	dose 97862 97867	3 MIU
T1180	tradename 97876 97883	PEGASYS
T1181	dose 97884 97891	180 mcg
T1182	tradename 98145 98152	PEGASYS
T1183	dose 98207 98242	6 million international units (MIU)
T1184	frequency 98243 98284	three times a week for the first 12 weeks
T1185	dose 98297 98327	3 million international units
T1186	frequency 98328 98359	three times a week for 36 weeks
T1187	routeofadministration 98366 98381	subcutaneously.
T1188	tradename 98875 98882	PEGASYS
T1189	dose 98883 98890	180 mcg
T1190	tradename 99054 99061	PEGASYS
T1191	indication 99225 99244	Chronic Hepatitis B
T1192	tradename 99262 99269	PEGASYS
T1193	tradename 99314 99321	PEGASYS
T1194	indication 99343 99362	chronic hepatitis B
T1195	indication 99478 99498	chronic hepatitis B.
T1196	tradename 99528 99535	PEGASYS
T1197	dose 99536 99543	180 mcg
T1198	routeofadministration 99544 99556	subcutaneous
T1199	frequency 99557 99569	once weekly,
T1200	tradename 99570 99577	PEGASYS
T1201	dose 99578 99585	180 mcg
T1202	routeofadministration 99586 99598	subcutaneous
T1203	frequency 99599 99610	once weekly
T1204	co-administereddrug 99625 99635	lamivudine
T1205	dose 99636 99642	100 mg
T1206	frequency 99643 99653	once daily
T1207	routeofadministration 99654 99662	by mouth
T1208	co-administereddrug 99666 99676	lamivudine
T1209	dose 99677 99683	100 mg
T1210	frequency 99684 99694	once daily
T1211	routeofadministration 99695 99704	by mouth.
T1212	tradename 99837 99844	PEGASYS
T1213	tradename 99851 99858	PEGASYS
T1214	indication 100205 100224	chronic hepatitis B
T1215	tradename 100645 100652	PEGASYS
T1216	tradename 100883 100890	PEGASYS
T1217	tradename 100920 100927	PEGASYS
T1218	tradename 101807 101814	PEGASYS
T1219	tradename 101905 101912	PEGASYS
T1220	tradename 102014 102021	PEGASYS
T1221	tradename 102082 102089	PEGASYS
T1222	tradename 102368 102375	PEGASYS
T1223	tradename 102501 102508	PEGASYS
T1224	tradename 103035 103042	PEGASYS
T1225	tradename 103124 103131	PEGASYS
T1226	tradename 103227 103234	PEGASYS
T1227	tradename 103295 103302	PEGASYS
T1228	tradename 103402 103409	PEGASYS
T1229	tradename 103507 103514	PEGASYS
T1230	tradename 103657 103664	PEGASYS
T1231	tradename 104528 104535	PEGASYS
T1232	co-administereddrug 104833 104842	ribavirin
T1233	co-administereddrug 104932 104941	Ribavirin
T1234	co-administereddrug 105299 105308	ribavirin
T1235	co-administereddrug 105841 105850	ribavirin
T1236	co-administereddrug 105961 105970	Ribavirin
T1237	tradename 106630 106638	PEGASYS;
T1238	tradename 106810 106817	PEGASYS
T1239	indication 107022 107033	hepatitis C
T1240	indication 107138 107149	hepatitis C
T1241	tradename 107649 107656	PEGASYS
T1242	tradename 108254 108262	PEGASYS.
T1243	tradename 108424 108431	PEGASYS
T1244	tradename 109684 109691	PEGASYS
T1245	company 109710 109732	Hoffmann-La Roche Inc.
T1246	company 109751 109774	Hoffmann-La Roche, Inc.
T1247	company 109779 109794	Genentech, Inc.
T1248	company 109811 109822	Roche Group
T1249	company 109885 109904	Genentech USA, Inc.
T1250	company 109921 109932	Roche Group
T1251	company 109985 110000	Genentech, Inc.
